Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Rima Al-awar"'
Autor:
Safoura Zangiabadi, Tania H. Watts, Methvin Isaac, Achire N. Mbanwi, Jaclyn C. Law, Michael Prakesch, Maria I. Edilova, Rima Al-awar, Kenneth Ting, Ali A. Abdul-Sater, Mark D. Minden, Andrea Arruda, David Uehling
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Oncoimmunology
article-version (VoR) Version of Record
Oncoimmunology
article-version (VoR) Version of Record
TRAF1 is a pro-survival adaptor molecule in TNFR superfamily (TNFRSF) signaling. TRAF1 is overexpressed in many B cell cancers including refractory chronic lymphocytic leukemia (CLL). Little has been done to assess the role of TRAF1 in human cancer.
Autor:
Janet Rossant, Trevor D. McKee, Rima Al-awar, Ahmed Aman, Richard Marcellus, Sean E. Egan, Amanda J. Loch, Christine E.B. Jo, Jessica R. Adams, David Uehling, Christopher Fladd, Lamis Hammoud
Publikováno v:
Stem Cell Reports, Vol 7, Iss 4, Pp 787-801 (2016)
Stem Cell Reports
Stem Cell Reports
Summary Blood vessels are formed through vasculogenesis, followed by remodeling of the endothelial network through angiogenesis. Many events that occur during embryonic vascular development are recapitulated during adult neoangiogenesis, which is cri
Autor:
Rosemarie Venier, Rima Al-awar, Brendan C. Dickson, Leah Kabaroff, Paul C. Boutros, Rebecca A. Gladdy, Methvin Isaac, Ren X. Sun, Yael Babichev, Michael Prakesch, David Uehling, Alessandro Datti
Publikováno v:
Journal of translational medicine, vol 14, iss 1
Journal of Translational Medicine
Journal of Translational Medicine
Background Leiomyosarcoma (LMS) is a common type of soft tissue sarcoma that responds poorly to standard chemotherapy. Thus the goal of this study was to identify novel selective therapies that may be effective in leiomyosarcoma by screening cell lin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c8e620ed66bb55ed38279fac83d8a6c
https://escholarship.org/uc/item/62z726sr
https://escholarship.org/uc/item/62z726sr
Autor:
Rima Al-awar, Methvin Isaac, Mark D. Minden, Jeff Wrana, John E. Dick, Faiyaz Notta, Kolja Eppert, Sean P. McDermott, Alessandro Datti
Publikováno v:
Blood. 119:1200-1207
Gene regulatory networks that govern hematopoietic stem cells (HSCs) and leukemia-initiating cells (L-ICs) are deeply entangled. Thus, the discovery of compounds that target L-ICs while sparing HSC is an attractive but difficult endeavor. Presently,
Autor:
David O'Neill, Amy M. Ruschak, Aaron D. Schimmer, Suzanne Trudel, Rose Hurren, Zhihua Li, Aisha Shamas-Din, Ahmed Aman, Rima Al-awar, Xioaming Wang, Lewis E. Kay, Zezhou Wang, Malik Slassi, Barry Press, Peter Dove, Carly Griffin, A Nachman, Y J Oh, S Climie, Elijus Undzys
Publikováno v:
Cell Death & Disease
Approved proteasome inhibitors have advanced the treatment of multiple myeloma but are associated with serious toxicities, poor pharmacokinetics, and most with the inconvenience of intravenous administration. We therefore sought to identify novel ora
Autor:
Owen Stechishin, Ahmed Aman, Natalie Grinshtein, David Kaplan, David Uehling, Artee Luchman, Samuel Weiss, Stephanie A. Nguyen, Rima al-Awar
BACKGROUND: Glioblastoma (GBM) is a devastating disease and the most lethal of adult brain tumours. Despite standard surgery, radiation and chemotherapy, the median survival is 15 months, thought to be due, in part, to recurrence from a small reservo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cc098e8da54582b6ac4e7a5ecce0c47
https://europepmc.org/articles/PMC4144593/
https://europepmc.org/articles/PMC4144593/
Autor:
Neil MacLean, Wissam Hadri, David O'Neill, Rose Hurren, Peter Dove, Aisha Shamas-Din, Marcela Gronda, Malik Slassi, Clarissa Skorupski, Ahmed Aman, Janessa Li, Zezhou Wang, Rima Al-awar, Aaron D. Schimmer, Feng Bo, Mark D. Minden, Xiaoming Wang
Publikováno v:
Blood. 126:1364-1364
Recent studies have demonstrated the therapeutic potential of targeting BRD2, BRD3 and BRD4 in hematological malignancies including AML. Here, we report a novel orally bioavailable BRD inhibitor, FV-281, that displays preclinical efficacy in AML in v
Autor:
Zezhou Wang, Peter Dove, Xiaoming Wang, Carolyn A. Goard, Zhihua Li, Alex Nachman, Yoonsun Jenny Oh, Rose Hurren, Amy Ruschak, Shane Climie, David O'Neill, Barry Press, Carly Griffin, Elijus Undzys, Ahmed Aman, Rima Al-awar, Lewis Kay, Suzanne Trudel, Malik Slassi, Aaron Schimmer
Publikováno v:
Blood. 122:1988-1988
Proteasome inhibitors (PIs), such as bortezomib and carfilzomib, are often associated with serious toxicities, poor pharmacokinetics (PK), and the inconvenience of intravenous administration. Therefore, there is a need for safer and more effective or
Autor:
Rod Bremner, Ahmed Aman, Rima Al-awar, Sean R. McCurdy, D. Chen, Monika Sangwan, Izhar Livne-Bar
Publikováno v:
Cancer Research. 72:2590-2590
Over the past few decades, extensive mouse and human genetics have implicated deregulated E2f and Cdk activity in cell exit escape and tumorigenesis. In flies, activating E2f or Cdk causes temporary abnormal division, but both must be induced for lon